Used in cancer immunotherapy to block the CD73 enzyme, which plays a role in suppressing the immune response within the tumor microenvironment. By inhibiting CD73, this antibody helps restore the activity of immune cells, particularly T cells and natural killer cells, enhancing their ability to recognize and destroy cancer cells. It is being investigated in clinical trials for solid tumors, including breast cancer, non-small cell lung cancer, and melanoma, often in combination with other immunotherapies like PD-1/PD-L1 inhibitors. Its application aims to overcome immune resistance and improve patient outcomes in cancers where CD73 is overexpressed.